Diabetic Peripheral Neuropathy - Pipeline Review, H2 2020
- $ 2000
- April 2024
- 97 pages
The presentations are entitled as "ACY-##, a Selective Histone Deacetylase (HDAC) ## Inhibitor: Interim Results of Combination Therapy with Bortezomib in Patients with Multiple Myeloma (MM)", "ACY-##, a First-In-Class Selective Inhibitor of HDAC6, Demonstrates Significant Synergy with Immunomodulatory Drugs (IMiDs) in Preclinical Models of Multiple Myeloma", "Discovery Histone Deacetylase (HDAC)## Specific Proteomic Biomarkers in Multiple Myeloma (MM) Using Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC)", "ACY-##, a Selective Histone Deacetylase (HDAC) ## Inhibitor, in Combination with Lenalidomide and Dexamethasone (dex), is Well Tolerated Without Dose Limiting Toxicity (DLT) in Patients with Multiple Myeloma at Doses Demonstrating Biologic Activity: Interim Results of a Phase Ib Trial", "Tubulin Hyper-Acetylation in Blood Lymphocytes: Pharmacodynamic (PD) Biomarker for the Selective Histone Deacetylase (HDAC) ## Inhibitor ACY-## in Multiple Myeloma Patients", "Preclinical Combination of the Oral Investigational Agents ACY-##, a Selective HDAC6 Inhibitor, and Ixazomib, a Proteasome Inhibitor, Demonstrates Combination Benefit in Multiple Myeloma Cell Lines and Xenograft Models", "Inhibition of Autophagy by ACY-##, a Selective HDAC6 Inhibitor, Accelerates Carfilzomib-Induced Cell Death in Multiple Myeloma", "Dual Targeting with the Selective Histone Deacetylase (HDAC) ## Inhibitor, ACY-##, and Bortezomib (BOR) Leads to Marked Disruption of Protein Degradation Pathways and Apoptosis in Preclinical Models of Lymphoma" and "Inhibition of HDAC6 in Combination with Targeted Agents Results in Broad Synergistic Decreases in Viability in Non-Hodgkin s Lymphoma (NHL) Cells".